Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vericel Corporation (VCEL)

28.47   -0.34 (-1.18%) 03-24 11:15
Open: 28.51 Pre. Close: 28.81
High: 28.65 Low: 28.04
Volume: 31,065 Market Cap: 1,348(M)

Technical analysis

as of: 2023-03-24 10:48:35 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 35.27     One year: 36.92
Support: Support1: 27.92    Support2: 23.22
Resistance: Resistance1: 30.2    Resistance2: 31.61
Pivot: 29.83
Moving Average: MA(5): 29.19     MA(20): 30.01
MA(100): 26.61     MA(250): 27.38
MACD: MACD(12,26): -0.1     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 16.8     %D(3): 31.5
RSI: RSI(14): 44.1
52-week: High: 40.34  Low: 17.29
Average Vol(K): 3-Month: 415 (K)  10-Days: 374 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VCEL ] has closed above bottom band by 10.3%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 29.33 - 29.47 29.47 - 29.6
Low: 28.01 - 28.16 28.16 - 28.31
Close: 28.55 - 28.8 28.8 - 29.03

Company Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Headline News

Sun, 05 Mar 2023
Gamco Investors INC. ET AL acquires 11,185 shares of Vericel Co ... - Best Stocks

Fri, 03 Mar 2023
Vericel Corp (VCEL) Stock: What Does the Chart Say Friday? - InvestorsObserver

Tue, 28 Feb 2023
Vericel to Present at the Canaccord Genuity Musculoskeletal ... - GlobeNewswire

Tue, 28 Feb 2023
Vericel Earnings Perspective: Return On Capital Employed - Vericel (NASDAQ:VCEL) - Benzinga

Thu, 23 Feb 2023
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance - Yahoo Finance

Thu, 23 Feb 2023
Vericel Corp Ord earnings beat by $0.08, revenue fell short of ... - India

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 47 (M)
Shares Float 44 (M)
% Held by Insiders 0.7 (%)
% Held by Institutions 112.6 (%)
Shares Short 5,830 (K)
Shares Short P.Month 6,110 (K)

Stock Financials

EPS 0.05
EPS Est Next Qtl -0.1
EPS Est This Year -0.63
EPS Est Next Year -0.38
Book Value (p.s.) 2.93
Profit Margin (%) -11.4
Operating Margin (%) -12
Return on Assets (ttm) -5.1
Return on Equity (ttm) -10.9
Qtrly Rev. Growth 11.6
Gross Profit (p.s.) 2.24
Sales Per Share 3.37
EBITDA (p.s.) -0.33
Qtrly Earnings Growth 0
Operating Cash Flow 21 (M)
Levered Free Cash Flow 17 (M)

Stock Valuations

PE Ratio 475.33
PEG Ratio 0
Price to Book value 9.73
Price to Sales 8.45
Price to Cash Flow 63.34

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.